Arrayit protein microarrays contain miniaturized collections of intact proteins, the molecules that comprise the building blocks of all living organisms including humans, plants and animals. These protein microarrays provide researchers with the tools necessary to study the structure and function of proteins, which are integral to understanding diverse fundamental research topics such as pharmaceutical compounds, human disease progression, synthetic and stem cell biology, ecology and population genetics.
Arrayit has been selling its patented microarray technology since 1997, and has installed its foundational technology in more than 4,000 laboratories to manufacture an estimated 100 million microarray devices.
The company recently completed a $1 million equity capital raise as well as opened new and expanded Sunnyvale headquarters, which will feature CLIA and ISO laboratories certified with the assistance of DOCRO, an Oxford, Connecticut-based clinical research organization. DOCRO is also assisting the company with its 510(k) submissions to the FDA for OvaDx® and PDx™, the company’s pre-symptomatic diagnostic tests for ovarian cancer and Parkinson’s disease.
For more information, visit www.arrayit.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
